Jens Hillengaß

20.4k total citations
188 papers, 4.2k citations indexed

About

Jens Hillengaß is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Jens Hillengaß has authored 188 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 164 papers in Hematology, 82 papers in Oncology and 78 papers in Molecular Biology. Recurrent topics in Jens Hillengaß's work include Multiple Myeloma Research and Treatments (161 papers), Protein Degradation and Inhibitors (37 papers) and Cancer Treatment and Pharmacology (32 papers). Jens Hillengaß is often cited by papers focused on Multiple Myeloma Research and Treatments (161 papers), Protein Degradation and Inhibitors (37 papers) and Cancer Treatment and Pharmacology (32 papers). Jens Hillengaß collaborates with scholars based in Germany, United States and France. Jens Hillengaß's co-authors include Hartmut Goldschmidt, Stefan Delorme, Kai Neben, Anthony D. Ho, Dirk Hose, Thomas Hielscher, Thomas Moehler, Ola Landgren, Hans‐Ulrich Kauczor and Anja Seckinger and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Jens Hillengaß

183 papers receiving 4.1k citations

Peers

Countries citing papers authored by Jens Hillengaß

Since Specialization

Citations

This map shows the geographic impact of Jens Hillengaß's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jens Hillengaß with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jens Hillengaß more than expected).

Fields of papers citing papers by Jens Hillengaß

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jens Hillengaß. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jens Hillengaß. The network helps show where Jens Hillengaß may publish in the future.

Co-authorship network of co-authors of Jens Hillengaß

This figure shows the co-authorship network connecting the top 25 collaborators of Jens Hillengaß. A scholar is included among the top collaborators of Jens Hillengaß based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jens Hillengaß. Jens Hillengaß is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma 2025 ·Blood ·(unknown), Qi Yan, Saeed Daneshmandi, Romain Lannes, Eriko Katsuta, (unknown), Prashant Kumar Singh, Ahmed Belal, Ronald Alberico, (unknown), Michele L. Schaefer, (unknown), (unknown), (unknown), Nikhil Munshi, Mehmet Samur, Philip L. McCarthy, Jens Hillengaß, Hemn Mohammadpour	1
2	Spot Urine Protein/Creatinine Ratio as an Alternative to 24-Hour Urine Collection for Measuring Proteinuria in Patients With Multiple Myeloma: A Prospective Study 2025 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), (unknown), (unknown), (unknown), (unknown), Jens Hillengaß	1
3	Differences in Immune Cell Populations between Individuals with or without MGUS 2024 ·Blood ·(unknown), (unknown), Alan D. Hutson, (unknown), Joseph D. Tario, (unknown), Scott I. Abrams, Jens Hillengaß	0
4	Prognostic factors for progression of MGUS including immune phenotype. 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), Alan D. Hutson, (unknown), Joseph D. Tario, Jens Hillengaß	1
5	Identification of focal lesion characteristics in MRI which indicate presence of corresponding osteolytic lesion in CT in patients with multiple myeloma 2023 ·Bone ·(unknown), André Klein, Klaus Maier‐Hein, (unknown), Stefan Delorme, Hartmut Goldschmidt, Jens Hillengaß	3
6	Dietary risk factors for monoclonal gammopathy of undetermined significance in a racially diverse population 2023 ·Blood Advances ·(unknown), Jens Hillengaß, Li Tang, Alexander M. Lesokhin, Ola Landgren, Saad Z. Usmani, Kirsten B. Moysich, Susan E. McCann, Urvi A. Shah	4
7	Imaging of treatment response and minimal residual disease in multiple myeloma: state of the art WB-MRI and PET/CT 2021 ·Skeletal Radiology ·Frédéric Lecouvet, Marie‐Christiane Vekemans, (unknown), Koenraad Verstraete, Thomas Kirchgesner, Souad Acid, Jacques Malghem, (unknown), Jens Hillengaß, Vincent Vandecaveye, François Jamar, Olivier Gheysens, Bruno C. Vande Berg	25
8	Serological Response to Vaccination after Autologous Transplantation for Multiple Myeloma Is Associated with Improved Progression-Free and Overall Survival 2020 ·Transplantation and Cellular Therapy ·(unknown), Maximilian Merz, Yali Zhang, (unknown), (unknown), George L. Chen, (unknown), Hemn Mohammadpour, Megan M. Herr, Amro Elshoury, Jens Hillengaß, Philip L. McCarthy, Theresa Hahn	3
9	Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling 2019 ·Biology of Blood and Marrow Transplantation ·Sarah A. Holstein, Zaid Al‐Kadhimi, Luciano J. Costa, Theresa Hahn, Parameswaran Hari, Jens Hillengaß, Allison P. Jacob, Nikhil C. Munshi, Stefania Oliva, Marcelo C. Pasquini, Qian Shi, Edward A. Stadtmauer, (unknown), Philip L. McCarthy	12
10	Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS) 2019 ·Radiology ·Christina Messiou, Jens Hillengaß, Stefan Delorme, Frédéric Lecouvet, Lia A. Moulopoulos, David J. Collins, Matthew Blackledge, Niels Abildgaard, Brian Østergaard, Heinz-Peter Schlemmer, Ola Landgren, Jon Thor Asmussen, Martin Kaiser, Anwar R. Padhani	218
11	Association of resilience with health-related quality of life and depression in multiple myeloma and its precursors: results of a German cross-sectional study 2018 ·BMJ Open ·Imad Maatouk, (unknown), Natália Becker, Manuela Hummel, (unknown), (unknown), Hartmut Goldschmidt, Mechthild Hartmann, Dieter Schellberg, Wolfgang Herzog, Jens Hillengaß	11
12	CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma—Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance 2018 ·Frontiers in Immunology ·Anja Seckinger, Jens Hillengaß, Martina Emde, Susanne Beck, Christoph Kimmich, Tobias Dittrich, Michael Hundemer, Anna Jauch, Ute Hegenbart, Marc‐Steffen Raab, Anthony D. Ho, Stefan Schönland, Dirk Hose	32
13	Quantitative analysis of 18F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myeloma. 2017 ·PubMed Central ·Christos Sachpekidis, Jens Hillengaß, Hartmut Goldschmidt, Hoda Anwar, Uwe Haberkorn, Antonia Dimitrakopoulou‐Strauss	7
14	High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting 2017 ·BMC Cancer ·Katharina Lisenko, Sandra Sauer, Thomas Brückner, Gerlinde Egerer, Hartmut Goldschmidt, Jens Hillengaß, (unknown), (unknown), Mathias Witzens‐Harig, Anthony D. Ho, Patrick Wuchter	14
15	Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma 2014 ·Transfusion ·(unknown), Michael Schmitt, Patrick Wuchter, Eike C. Buss, Mathias Witzens‐Harig, Kai Neben, Michael Hundemer, Jens Hillengaß, (unknown), Hartmut Goldschmidt, (unknown), Anthony D. Ho, Anita Schmitt	33
16	Assessing Treatment Response of Osteolytic Lesions by Manual Volumetry, Automatic Segmentation, and RECIST in Experimental Bone Metastases 2014 ·Academic Radiology ·(unknown), (unknown), Maximilian Merz, Jens Hillengaß, Wolfhard Semmler, Rolf Bendl, Tobias Bäuerle	6
17	Bisphosphonate treatment and renal function in 201 myeloma patients undergoing stem cell transplantation 2013 ·International Journal of Hematology ·Stefan Schmitt, Thomas Hielscher, Claudia D. Baldus, Kai Neben, Gerlinde Egerer, Jens Hillengaß, Marc‐Steffen Raab, Dirk Hose, Anthony D. Ho, Raoul Bergner, Hartmut Goldschmidt, Thomas Moehler	2
18	Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients With Asymptomatic Multiple Myeloma 2010 ·Journal of Clinical Oncology ·Jens Hillengaß, Kerstin Fechtner, Marc‐André Weber, Tobias Bäuerle, (unknown), Christiane Heiß, Thomas Hielscher, Thomas Moehler, Gerlinde Egerer, Kai Neben, Anthony D. Ho, Hans‐Ulrich Kauczor, Stefan Delorme, Hartmut Goldschmidt	255
19	Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: Importance of Whole-Body versus Spinal MR Imaging 2009 ·Radiology ·Tobias Bäuerle, Jens Hillengaß, Kerstin Fechtner, Christian M. Zechmann, Lars Grenacher, Thomas Moehler, (unknown), (unknown), Kai Neben, Hans‐Ulrich Kauczor, Hartmut Goldschmidt, Stefan Delorme	87
20	Funktioelle Magnetresonanztomographie in Diagnostik und Therapiemonitoring beim Multiplen Myelom 2000 ·Der Radiologe ·Thomas Moehler, H. Hawighorst, Kai Neben, Gerlinde Egerer, Axel Benner, Jens Hillengaß, Regina Max, A. D. Ho, Hartmut Goldschmidt, G. van Kaick	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact